Evidence map›Paper›PMID 36012761›Full record

ArticleInternational journal of molecular sciences2022

Differences in Expression of

Beatriz Baladron, Lidia M Mielu, Estrella López-Martín, Maria J Barrero, Lidia Lopez, Jose I Alvarado, Sara Monzón, Sarai Varona, Isabel Cuesta, Rosario Cazorla and 12 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Frontiers in pediatrics · 2026
    Article
  3. Article
  4. Natural Course ofChildren (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Beatriz BaladronInstituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain.
Lidia M MieluInstituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain.
Estrella López-MartínInstituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain.ORCID 0000-0003-3212-1424
Maria J BarreroInstituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain.ORCID 0000-0002-5990-7040
Lidia LopezInstituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain.
Jose I AlvaradoInstituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain.
Sara MonzónBioinformatics Unit, Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain.
Sarai VaronaBioinformatics Unit, Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain.
Isabel CuestaBioinformatics Unit, Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain.
Rosario CazorlaNeuropediatrics Service, Hospital Puerta de Hierro, 28222 Madrid, Spain.
Julián LaraNeuropediatrics Service, Hospital Puerta de Hierro, 28222 Madrid, Spain.
Gemma IglesiasNeuropediatrics Service, Hospital Puerta de Hierro, 28222 Madrid, Spain.
Enriqueta RománNeuropediatrics Service, Hospital Puerta de Hierro, 28222 Madrid, Spain.
Purificación RosNeuropediatrics Service, Hospital Puerta de Hierro, 28222 Madrid, Spain.
Gema Gomez-MarianoInstituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain.
Isabel CubilloInstituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain.
Esther Hernandez-San MiguelInstituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain.
Daniel RiveraInstituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain.
Javier AlonsoInstituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain.ORCID 0000-0002-6287-8391
Eva Bermejo-SánchezInstituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain.ORCID 0000-0001-7282-2714
Manuel PosadaInstituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain.ORCID 0000-0002-8372-4180
Beatriz Martínez-DelgadoInstituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain.ORCID 0000-0001-6834-350X
Instituto de Salud Carlos III · ESHospital Universitario Puerta de Hierro Majadahonda · ES

Funding

Instituto de Salud Carlos III PT20CIII/00009Instituto de Salud Carlos III SpainUDP program
6 · The paper itself

Abstract

Pathogenic hemizygous or heterozygous mutations in the IQSEC2 gene cause X-linked intellectual developmental disorder-1 (XLID1), characterized by a variable phenotype including developmental delay, intellectual disability, epilepsy, hypotonia, autism, microcephaly and stereotypies. It affects both males and females typically through loss of function in males and haploinsufficiency in heterozygous females. Females are generally less affected than males. Two novel unrelated cases, one male and one female, with de novo IQSEC2 variants were detected by trio-based whole exome sequencing. The female case had a previously undescribed frameshift mutation (NM_001111125:c.3300dup; p.Met1101Tyrfs*5), and the male showed an intronic variant in intron 6, with a previously unknown effect (NM_001111125:c.2459+21C>T). IQSEC2 gene expression study revealed that this intronic variant created an alternative donor splicing site and an aberrant product, with the inclusion of 19bp, confirming the pathogenic effect of the intron variant. Moreover, a strong reduction in the expression of the long, but also the short IQSEC2 isoforms, was detected in the male correlating with a more severe phenotype, while the female case showed no decreased expression of the short isoform, and milder effects of the disease. This suggests that the abnormal expression levels of the different IQSEC2 transcripts could be implicated in the severity of disease manifestations.

Indexed as

Guanine Nucleotide Exchange FactorsIntellectual DisabilityNeurodevelopmental DisordersExome SequencingFemaleHumansMaleMutationPedigreePhenotypeProtein IsoformsGuanine Nucleotide Exchange FactorsIQSEC2 protein, humanProtein Isoformsexomegene expressionintron variantIQSEC2 geneneurodevelopment syndromeSpainUDPtranscript isoforms

Identifiers

PMID36012761
PMCPMC9409358
OpenAlexW4292687301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.